Abstract
Retinoic acid (RA) induces the differentiation of tumor cells of neural origin and may do so by binding to one or more nuclear receptor proteins. We have identified transcripts and nuclear RA receptor (RAR) protein in a clonal line of human neuroblastoma cells that differentiate in response to RA. Prior to any exposure to RA, LA1-15n cells express two transcripts for RARa (3.6 and 2.7 kb) as well as low levels of transcript for RARα (3.4) and RARγ (2.8 kb). Exposure of LA1-15n cells to RA leads to the induction of a 2.9-kb RARβ mRNA, whereas the expression of transcripts for RARs α and γ does not change appreciably. The 2.9-kb RARβ transcript is increased by 4 h (8-fold) and continues to increase for 24-48 h (40- to 60-fold). The RA-associated increase in RARβ mRNA in LA1-15n cells is not diminished by the addition of the protein synthesis inhibitor, cycloheximide, but is abolished by the addition of the RNA synthesis inhibitor, actinomycin D. In addition to RAR transcripts, LA 1-15n cells contain a nuclear protein with the requisite characteristics of a RAR. The nuclear protein binds all-trans-[3H]RA with high affinity (Kd 0.2 nM). The nuclear protein sediments at 4S, which is consistent with the molecular mass deduced from RAR cDNAs (50,000 Da). The nuclear protein is clearly distinguishable from a all-trans-[3H]RA-binding protein found in the cytosolic fraction of LAl-iSa cells. The cytosolic protein sediments at 2S on sucrose density gradients, consistent with the expected molecular mass of the cellular retinoic acid-binding protein (16,000 Da). The nuclear [3H]RA-binding protein binds to DNA-cellulose and to the RARfl response element. These results support the hypothesis that RARs are present in human neuroblastoma cells and may be involved in human neuroblastoma cell differentiation. They also demonstrate that RA markedly influences the expression of steady-state levels of mRNA for one of its own receptors, the RARβ.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.